Biodegradable Gelatin Microparticles As Delivery Systems for the Controlled Release of Bone Morphogenetic Protein-2

Overview

Journal Acta Biomater

Publisher Elsevier

Specialty Biomedical Engineering

Date 2008 May 14

PMID 18474452

Citations 88

Authors

Zarana S Patel

Masaya Yamamoto

Hiroki Ueda

Yasuhiko Tabata

Antonios G Mikos

Affiliations

Soon will be listed here.

Abstract

This work evaluated gelatin microparticles and biodegradable composite scaffolds for the controlled release of bone morphogenetic protein-2 (BMP-2) in vitro and in vivo. Gelatin crosslinking (10 and 40mM glutaraldehyde), BMP-2 dose (6 and 60ng BMP-2 per mg dry microparticles), buffer type (phosphate buffered saline (PBS) and collagenase-containing PBS), and gelatin type (acidic and basic) were investigated for their effects on BMP-2 release. Release profiles were also observed using poly(lactic-co-glycolic acid) (PLGA) microparticles with varying molecular weights (8300 and 57,500). In vitro and in vivo studies were conducted using radiolabeled BMP-2; the chloramine-T method was preferred over Bolton-Hunter reagent for radioiodination with this system. BMP-2 release from PLGA microparticles resulted in a moderate burst release followed by minimal cumulative release, while BMP-2 release from gelatin microparticles exhibited minimal burst release followed by linear release kinetics in vitro. Growth factor dose had a small effect on its normalized release kinetics probably because of an equilibrium between gelatin-bound and unbound BMP-2. Differences in release from acidic and basic gelatin microparticles may result from the different pretreatment conditions used for gelatin synthesis. The in vitro release kinetics for both gelatin microparticles alone and within composite scaffolds were dependent largely on the extent of gelatin crosslinking; varying buffer type served to confirm that controlled release relies on enzymatic degradation of the gelatin for controlled release. Finally, in vivo studies with composite scaffolds exhibited minimal burst and linear release up to 28 days. In summary, dose effects on BMP-2 release were found to be minimal while varying gelatin type and release medium can alter release kinetics. These results demonstrate that a systematic control of BMP-2 delivery from gelatin microparticles can be achieved by altering the extent of basic gelatin crosslinking.

Citing Articles

Characterization of a Delivery System Based on a Hyaluronic Acid 3D Scaffold and Gelatin Microparticles.

Martinez-Ramos C, Rodriguez Ruiz A, Monleon Pradas M, Gisbert Roca F Polymers (Basel). 2024; 16(12).

PMID: 38932096 PMC: 11207266. DOI: 10.3390/polym16121748.

Stem cell exosome-loaded Gelfoam improves locomotor dysfunction and neuropathic pain in a rat model of spinal cord injury.

Poongodi R, Yang T, Huang Y, Yang K, Chen H, Chu T Stem Cell Res Ther. 2024; 15(1):143.

PMID: 38764049 PMC: 11103960. DOI: 10.1186/s13287-024-03758-5.

MicroRNA-200c Release from Gelatin-Coated 3D-Printed PCL Scaffolds Enhances Bone Regeneration.

Remy M, Upara C, Ding Q, Miszuk J, Sun H, Hong L ACS Biomater Sci Eng. 2024; 10(4):2337-2350.

PMID: 38531043 PMC: 11005014. DOI: 10.1021/acsbiomaterials.3c01105.

Mineralized collagen scaffolds for regenerative engineering applications.

Kolliopoulos V, Harley B Curr Opin Biotechnol. 2024; 86:103080.

PMID: 38402689 PMC: 10947798. DOI: 10.1016/j.copbio.2024.103080.

Human Mesenchymal Stem Cells on Size-Sorted Gelatin Hydrogel Microparticles Show Enhanced In Vitro Wound Healing Activities.

Ozhava D, Bektas C, Lee K, Jackson A, Mao Y Gels. 2024; 10(2).

PMID: 38391427 PMC: 10887759. DOI: 10.3390/gels10020097.

References

Shung A, Behravesh E, Jo S, Mikos A . Crosslinking characteristics of and cell adhesion to an injectable poly(propylene fumarate-co-ethylene glycol) hydrogel using a water-soluble crosslinking system. Tissue Eng. 2003; 9(2):243-54. DOI: 10.1089/107632703764664710. View

Ueda H, Nakamura T, Yamamoto M, Nagata N, Fukuda S, Tabata Y . Repairing of rabbit skull defect by dehydrothermally crosslinked collagen sponges incorporating transforming growth factor beta1. J Control Release. 2003; 88(1):55-64. DOI: 10.1016/s0168-3659(02)00481-9. View

CORNELL C, Lane J . Current understanding of osteoconduction in bone regeneration. Clin Orthop Relat Res. 1999; (355 Suppl):S267-73. DOI: 10.1097/00003086-199810001-00027. View

Hedberg E, Kroese-Deutman H, Shih C, Crowther R, Carney D, Mikos A . In vivo degradation of porous poly(propylene fumarate)/poly(DL-lactic-co-glycolic acid) composite scaffolds. Biomaterials. 2005; 26(22):4616-23. DOI: 10.1016/j.biomaterials.2004.11.039. View

Kirker-Head C, Karageorgiou V, Hofmann S, Fajardo R, Betz O, Merkle H . BMP-silk composite matrices heal critically sized femoral defects. Bone. 2007; 41(2):247-55. PMC: 2695963. DOI: 10.1016/j.bone.2007.04.186. View

Duggirala S, Mehta R, Deluca P . Interaction of recombinant human bone morphogenetic protein-2 with poly(d,l lactide-co-glycolide) microspheres. Pharm Dev Technol. 1996; 1(1):11-9. DOI: 10.3109/10837459609031413. View

Kim B, Mooney D . Development of biocompatible synthetic extracellular matrices for tissue engineering. Trends Biotechnol. 1998; 16(5):224-30. DOI: 10.1016/s0167-7799(98)01191-3. View

Parks W . Matrix metalloproteinases in repair. Wound Repair Regen. 2000; 7(6):423-32. DOI: 10.1046/j.1524-475x.1999.00423.x. View

Kellomaki M, Niiranen H, Puumanen K, Ashammakhi N, Waris T, Tormala P . Bioabsorbable scaffolds for guided bone regeneration and generation. Biomaterials. 2000; 21(24):2495-505. DOI: 10.1016/s0142-9612(00)00117-4. View

10.

Schrier J, Deluca P . Recombinant human bone morphogenetic protein-2 binding and incorporation in PLGA microsphere delivery systems. Pharm Dev Technol. 1999; 4(4):611-21. DOI: 10.1081/pdt-100101400. View

11.

Wallkamm B, Schmid J, Hammerle C, Gogolewski S, Lang N . Effect of bioresorbable fibres (Polyfibre) and a bioresorbable foam (Polyfoam) on new bone formation. A short term experimental study on the rabbit skull. Clin Oral Implants Res. 2004; 14(6):734-42. DOI: 10.1046/j.0905-7161.2003.00930.x. View

12.

Bolton A, Hunter W . The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem J. 1973; 133(3):529-39. PMC: 1177731. DOI: 10.1042/bj1330529. View

13.

Yamamoto M, Takahashi Y, Tabata Y . Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials. 2003; 24(24):4375-83. DOI: 10.1016/s0142-9612(03)00337-5. View

14.

Murakami N, Saito N, Takahashi J, Ota H, Horiuchi H, Nawata M . Repair of a proximal femoral bone defect in dogs using a porous surfaced prosthesis in combination with recombinant BMP-2 and a synthetic polymer carrier. Biomaterials. 2003; 24(13):2153-9. DOI: 10.1016/s0142-9612(03)00041-3. View

15.

Kirker-Head C . Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Deliv Rev. 2000; 43(1):65-92. DOI: 10.1016/s0169-409x(00)00078-8. View

16.

Wang Y, Lin F, Sun J, Huang Y, Chueh S, Hsu F . Collagen-hydroxyapatite microspheres as carriers for bone morphogenic protein-4. Artif Organs. 2003; 27(2):162-8. DOI: 10.1046/j.1525-1594.2003.06953.x. View

17.

Geiger M, Li R, Friess W . Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev. 2003; 55(12):1613-29. DOI: 10.1016/j.addr.2003.08.010. View

18.

Saito N, Okada T, Horiuchi H, Murakami N, Takahashi J, Nawata M . A biodegradable polymer as a cytokine delivery system for inducing bone formation. Nat Biotechnol. 2001; 19(4):332-5. DOI: 10.1038/86715. View

19.

Schrier J, Deluca P . Porous bone morphogenetic protein-2 microspheres: polymer binding and in vitro release. AAPS PharmSciTech. 2004; 2(3):E17. PMC: 2750582. DOI: 10.1208/pt020317. View

20.

Whang K, Healy K, Elenz D, Nam E, Tsai D, Thomas C . Engineering bone regeneration with bioabsorbable scaffolds with novel microarchitecture. Tissue Eng. 1999; 5(1):35-51. DOI: 10.1089/ten.1999.5.35. View